alexa Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Stewart RA

Abstract Share this page

Abstract Evaluation of: Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008). The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized nearly 18,000 subjects with no history of cardiovascular disease and an average or low LDLcholesterol level (<3.4 mmol/l), but a high plasma level of C-reactive protein (CRP; >2 mg/dl), to rosuvastatin 20 mg or placebo daily. The trial was stopped early because of a highly statistically significant 46\% reduction in cardiovascular events for patients randomized to rosuvastatin. Participants who achieved an LDL-cholesterol level lower than 1.8 mmol/l and a CRP level lower than 2 mg/dl on treatment had the greatest decrease in cardiovascular risk. The JUPITER trial provides evidence that the benefits of statins relate in part to decreased inflammation. Comparison with other statin trials indicates that absolute cardiovascular risk is an important predictor of benefit from statin treatment, and potent statins that result in a greater percentage reduction in LDLcholesterol and CRP are likely to reduce risk more. Targeting statin treatment based on LDL-cholesterol alone will not provide an optimal risk reduction for many individuals. This article was published in Future Cardiol and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords